January 28, 2025

New Member: Welcome in our cluster to Akribion Therapeutics GmbH

New Member: Welcome in our cluster to Akribion Therapeutics GmbH
Go back

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence. This ensures that only the targeted cells are affected, leaving healthy cells unharmed.
Akribion is exploring applications in oncology, autoimmune diseases, fibrosis, and infectious diseases, as the technology can be quickly adapted to target different biomarkers and cells.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Ladenburg, Germany, 28 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its wholly-owned subsidiary, Heidelberg Pharma Research GmbH, has signed a new collaboration agreement with its strategic partner Huadong Medicine Co., Ltd., Hangzhou, China. Huadong Medicine is the second-largest shareholder of Heidelberg Pharma […]

read more
Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

Ladenburg, Germany, 26 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the […]

read more
Cells Have an Early-Warning System for Stress in Mitochondria

Cells Have an Early-Warning System for Stress in Mitochondria

Internal protective mechanism responds to the very first signs of mitochondrial dysfunction Mitochondria – the powerhouses of the cell – have their own monitoring system that detects oxidative stress at a very early stage. It activates protective mechanisms even before the damage caused by this stress can spread to the rest of the cell. This […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp